CCM
REGN icon

CAAS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

CAAS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,200
Closed -$580K – 1355
2020
Q4 		$580K Hold
1,200
– – 0.01% 673
2020
Q3 		$672K Hold
1,200
– – 0.02% 369
2020
Q2 		$748K Sell
1,200
-2,500
-68% -$1.42M 0.02% 288
2020
Q1 		$1.81M Buy
+3,700
New +$1.53M 0.19% 100

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's REGN Position: Q1 2022 in Review

CAAS Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 994 shares — an estimated $628K sold.

CAAS Capital Management first reported a position in REGN in Q2 2020 and held it in 6 quarters. The position peaked at $2.14M in Q1 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

  • CAAS Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 994 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $628K.
  • CAAS Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 6 quarters.
  • CAAS Capital Management's Regeneron Pharmaceuticals position peaked at $2.14M in Q1 2021.
  • 1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.